Updated Guidelines for the Programmatic Management of Drug-Resistant TB

This WHO document emphasizes the use of molecular diagnostics for rapid detection of drug resistance and provides treatment recommendations.

Target Population: Public health professionals involved in the prevention and control of drug-resistant tuberculosis (TB)

Sponsoring Organization: WHO

Type: Evidence-based consensus guidelines using a grading system

Key Points: This document updates and expands guidelines for diagnosing and treating multidrug-resistant TB (MDR-TB — i.e., infection with Mycobacterium tuberculosis resistant to at least isoniazid and rifampicin) that were first released in 2006 and were updated on an emergency basis in 2008.

Like the 2008 update, the 2011 recommendations emphasize using molecular techniques on positive TB cultures to rapidly detect resistance to rifampicin and isoniazid, the main anti-TB drugs. In situations where the likelihood of such resist…

Reviewing Author

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Updated Guidelines for the Programmatic Management of Drug-Resistant TB

Topics

Reviewing Author